We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| aTyr Pharma Inc | NASDAQ:ATYR | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.055 | -1.77% | 3.045 | 3.04 | 3.05 | 3.134 | 2.98 | 3.10 | 522,146 | 15:00:48 |
From Sep 2024 to Mar 2025
Details of the conferences appear below:
Conference: Stifel Healthcare ConferenceDate: Monday, November 18, 2024 Time: 3:35pm ESTLocation: New York, NYFormat: Corporate Presentation
Conference: Jefferies London Healthcare Conference Date: Wednesday, November 20, 2024Time: 3:00pm GMTLocation: London, UKFormat: Corporate Presentation
Conference: 7th Annual Evercore HealthCONx ConferenceDate: Tuesday, December 3, 2024Time: 8:20am ESTLocation: Coral Gables, FLFormat: Fireside Chat
Conference: Piper Sandler 36th Annual Healthcare ConferenceDate: Thursday, December 5, 2024Time: 12:00pm ESTLocation: New York, NYFormat: Fireside Chat
In addition to the presentations, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the conferences. A webcast of the presentations will be available on the Investor’s section of the company’s website at www.atyrpharma.com. Following the events, a replay of the presentations will be available on the aTyr website for at least 90 days. For more information, contact investorrelations@atyrpharma.com.
About aTyr
aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit www.atyrpharma.com.
| Contact: |
| Ashlee Dunston |
| Director, Investor Relations and Public Affairs |
| adunston@atyrpharma.com |
1 Year aTyr Pharma Chart |
1 Month aTyr Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
